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Abstract
Capecitabine (CAP) is a 5-FU pro-drug approved for the treatment of several cancers and it is used in combination with
gemcitabine (GEM) in the treatment of patients with pancreatic adenocarcinoma (PDAC). However, limited pre-clinical data
of the effects of CAP in PDAC are available to support the use of the GEMCAP combination in clinic. Therefore, we
investigated the pharmacokinetics and the efficacy of CAP as a single agent first and then in combination with GEM to
assess the utility of the GEMCAP therapy in clinic. Using a model of spontaneous PDAC occurring in KrasG12D; p53R172H;
Pdx1-Cre (KPC) mice and subcutaneous allografts of a KPC PDAC-derived cell line (K8484), we showed that CAP achieved
tumour concentrations (,25 mM) of 5-FU in both models, as a single agent, and induced survival similar to GEM in KPC
mice, suggesting similar efficacy. In vitro studies performed in K8484 cells as well as in human pancreatic cell lines showed
an additive effect of the GEMCAP combination however, it increased toxicity in vivo and no benefit of a tolerable GEMCAP
combination was identified in the allograft model when compared to GEM alone. Our work provides pre-clinical evidence of
5-FU delivery to tumours and anti-tumour efficacy following oral CAP administration that was similar to effects of GEM.
Nevertheless, the GEMCAP combination does not improve the therapeutic index compared to GEM alone. These data
suggest that CAP could be considered as an alternative to GEM in future, rationally designed, combination treatment
strategies for advanced pancreatic cancer.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading
cause of cancer-related deaths in industrialised countries. Overall
5 year survival rate is less than 5% [1]. The high degree of
mortality of PDAC is attributable to the lack of early detection
methods and the poor efficacy of existing therapies. Gemcitabine
(GEM) is the standard therapy, but the median survival time
remains only 5–7 months in patients with advanced disease [2].
Therefore, more effective treatment strategies are required.
Capecitabine (XelodaH; Hoffmann La Roche) is an orally
administered fluoropyrimidine carbamate, metabolised in liver
and tumour by carboxylesterases and cytidine deaminase to 59-
deoxy-5-fluorocytidine (59-DFCR) and 59-deoxy-5-fluorouridine
(59-DFUR) respectively. The final step of the activation of
capecitabine (CAP), conversion of 59-DFUR to cytotoxic 5-
fluorouracil (5-FU), is mediated by thymidine phosphorylase [3–
5], which is expressed more highly in neoplastic than normal
tissue, making CAP more tumour specific than 5-FU [5,6]. Anti-
tumour efficacy of CAP has been shown in numerous studies using
human cancer xenograft models of breast, colon, gastric, cervical,
bladder ovarian and prostate cancer (see for review [7]) but only
one study has been reported in a pancreas model [8] and this was
in an atypical KRAS wild type pancreatic cancer cell xenograft. In
the clinic, CAP is approved by the FDA as first line single agent
therapy in patients with metastatic colorectal cancer and for
metastatic breast cancer as a single agent or in combination with
docetaxel after failure of prior anthracyline-based chemotherapy.
In patients with completely resected pancreatic cancer, it has been
shown that combined intravenous bolus of 5-fluorouracil and
folinic acid (FUFA) is an active adjuvant therapy and the use of
FUFA is equivalent to GEM when overall survival is the end-point
[9,10]. In advanced PDAC, particularly in the UK, CAP has
replaced FUFA and is used in combination with GEM (GEM-
PLOS ONE | www.plosone.org 1 June 2013 | Volume 8 | Issue 6 | e67330
CAP), based on the results of the meta-analysis performed by
Heinemann and al. showing a modest but significant survival
benefit from the combination of GEM with a fluoropyrimidine
and especially with CAP [2]. A recent clinical study confirmed the
benefit of GEMCAP in unselected patients with advanced PDAC
[11].
In view of the limited pre-clinical data using CAP in PDAC,
in vivo studies were undertaken to evaluate CAP in a genetically
engineered mouse model of the disease. KrasG12D; p53R172H;
Pdx1-Cre (KPC) mice conditionally express endogenous mutant
Kras and p53 alleles in pancreatic cells [12] and develop
pancreatic tumours, which recapitulate the pathophysiological
aspects and the molecular features of human PDAC [13]. We also
used an allograft of a pancreatic cancer cell line (K8484) isolated
from a KPC PDAC. Pharmacokinetic and efficacy studies were
performed using single agent CAP and the combination of GEM
and CAP. Studies from the literature suggested an association
between cytidine deaminase (CDA) enzyme activity and the risk of
toxicity in patients receiving GEM or CAP-based therapy [14,15].
CDA is involved in the activation of CAP through the
deamination of dFCR into dFUR but is conversely responsible
for the deamination of GEM into its inactive metabolite dFdU
[4,5,16,17]. Because of the toxicity we observed with the
GEMCAP combination we quantified CDA enzyme activity in
the tumour tissue.
Materials and Methods
Mouse Strains
KPC mice develop advanced PDAC from 2 to 3 months and
have a shortened median survival of approximately 5 months
[12,18]. Their control littermates, Kras; p53R172H; Pdx1-Cre (PC)
mice were also used in this study to transplant subcutaneously the
K8484 cell line. Thus, all the experiments were performed using
mice from the same mixed 129/SvJal/C57BL/6 genetic back-
ground. All experiments were carried out in accordance with the
UK Animals (Scientific Procedures) Act 1986 with approval from
the local Animal Ethics Committee, and following the 2010
guidelines from the United Kingdom Coordinating Committee on
Cancer Research [19].
Cell Lines
The K8484 cell line was established from a KPC PDAC tumour
by Olive et al. [18,20]. Cells were grown in DMEM medium (Life
Technologies) supplemented with 5% fetal bovine serum (FBS).
The human pancreatic cancer cell lines Panc-1 and MiaPaCa-
2 were obtained from ECACC (Salisbury, UK) and grown in
DMEM with 10% FBS. The identity of all human cell lines were
verified by STR genotyping and tested negative for mycoplasma.
Cytotoxicity Assay
Drug cytotoxicity in vitro was assessed by the means of
Sulforhodamine B colorimetric (SRB) assay. Cells were plated in
a 96 well plate and dosed with a range of concentrations of 5-FU
(0.03 mM to 30 mM) in rows and gemcitabine (361024 mM to
0.3 mM) in columns, giving a grid of 868 concentration
combinations. After 72 h of incubation at 37uC, cells were then
fixed (3% trichloroacetic acid, 90 minutes, 4uC), washed in water
and stained with a 0.057% SRB (Sigma) solution in acetic acid (w/
v) for 30 minutes. The plates were washed (1% acetic acid, 4
times), and the protein-bound dye was dissolved in a 10 mM Tris
base solution (pH 10.5). Fluorescence was measured using Tecan
Infinite M200 plate-reader (excitation 488 nm, emission 585 nm).
The % Growth Inhibition (GI) compared to solvent control-
treated cells was calculated for each drug concentration combi-
nation.
The effect of the combination was evaluated using the Bliss
Independance model [21,22] according to the protocol we have
described previously [23]. Briefly, an additivity model was built
based on single agent data from 5-FU and GEM. GI values
obtained from this model were then subtracted from the
experimental values to identify regions of synergy and antagonism.
Negative numbers show less than additive effects (yellow to red
colour) and positive numbers show greater than additive effect
(green to blue).
Drug preparation
Capecitabine powder (Sequoia Research) was resuspended in a
40 mM citrate buffer and 5% gum Arabic at 100 mg/ml and
administered by oral gavage. Gemcitabine hydrochloride (Tocris
Bioscience) was dissolved in saline at 20 mg/ml and administered
by intraperitoneal injection.
Pharmacokinetics and Efficacy Studies in K8484 Allograft
Model
Bilateral K8484 allografts were obtained by subcutaneous
injection of 106 cells per flank. For pharmacokinetics studies,
mice bearing allograft tumour were treated with a single dose of
CAP at 755 mg/kg and samples were collected 10 min, 20 min,
40 min, 1 h, 2 h and 4 h after, three animals per time point. Blood
was collected in Lithium heparin, and plasma isolated and stored
at 280uC. Liver and tumours were removed and snap-frozen in
liquid nitrogen.
In CAP efficacy studies, mice were treated with CAP at
755 mg/kg or vehicle for 5 consecutive days per week for 3 weeks.
In GEMCAP combination efficacy study, mice received gemcita-
bine doses at 75 mg/kg, every 3 days alone or in combination
with oral CAP doses at 539 mg/kg given 5 days per week.
Tumours were measured using by callipers. Tumour volume was
calculated as length6width26p/6.
Efficacy and Survival Study in KPC Mouse Model
The enrolment of KPC mice in study was based on tumour size,
measured by ultrasound in an axial orientation. Mice with mean
PDAC tumour diameters of 6–9 mm were enrolled. For the short
term efficacy study, mice were treated with CAP at 755 mg/kg or
vehicle for 7 consecutive days. During treatment, mice were
imaged twice by high resolution ultrasound imaging using the
Vevo 770 System (Visual Sonics, Inc) [24] and tumour volumes
were quantified [18]. On day 7, mice were killed 2 h after the CAP
dose. Plasma, tumour and liver were collected as above. For the
survival study, mice were enrolled, and imaged every 3 days whilst
treating with CAP at 755 mg/kg for 5 consecutive days per week
or with GEM at 100 mg/kg every 3 days until the endpoint
criteria were reached. These included the development of
abdominal ascites, severe cachexia, significant weight loss
(approaching 20%) of initial weight or extreme weakness or
inactivity.
Immunohistochemistry
Formalin-fixed, paraffin embedded tissue sections were stained
using phospho-histone H3 antibody (Upstate, #06-570) and
detected using DAB Peroxidase Substrate (Vector Labs). Staining
was imaged and quantified using the Ariol system (Leica
Microsystems). A minimum of 3 fields per tumour were quantified.
PH3 positive cells were defined as those having positively staining
condensed chromatin.
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GEMCAP Combination Tolerance Studies
PC mice bearing K8484 cell allografts were treated with GEM
at 100 mg/kg or 75 mg/kg every 3 days alone or in combination
with CAP at 755 mg/kg or 539 mg/kg or 378 mg/kg, 5
consecutive days per week and were killed if any clinical signs
approached the permitted limits (which included diarrhoea,
haemorrhage and weight loss approaching 20%). Two animals
per dose were used. Tumour response was assessed by daily
measurement of the tumours with callipers.
Determination of Capecitabine and Metabolite
Concentrations in Plasma, Liver and Tumours
CAP, DFCR, DFUR and 5FU were determined both in plasma
and tissues using a modified version of the protocol previously
published [25]. Briefly, tissue samples were homogenised using a
Precellys 24 homogeniser with small ball bearings (Kit Precellys
MK28-R) for 2650 seconds at 6 000 rpm in ice-cold 50:50
acetonitrile:water (v/v) containing 25 mg/ml tetrahydrouridine
(Promega) to make a final concentration of 50 mg tissue per ml.
Fifty ml of homogenate was transferred to a clean tube prespiked
with 200 ml of ice-cold acetonitrile containing 50 ng/ml stable
labelled (SIL) internal standards of all 4 analytes (Toronto
Research Chemicals). After centrifugation at 20,000 g for 5
minutes the supernatant was evaporated to dryness, resuspended
in 100 mL of water and injected onto the LC-MS/MS. For plasma
samples, 50 mL of plasma was precipitated with 150 mL of
acetonitrile containing 50 ng/ml stable labelled internal standards
and processed similarly.
Detection was achieved by LC-MS/MS using a Thermo TSQ
Vantage mass spectrometer with a HESI-II probe operated in
positive and negative mode at a spray voltage of 3 kV and
vaporizer temperature of 325uC. Detection of the ions was
performed in the multiple reaction monitoring mode, specific for
each compound. Concentrations of capecitabine and metabolites
in samples were determined by comparison against calibration
lines constructed using authentic reference standards.
CDA Enzyme Activity
To prepare crude enzyme matrix, tumour tissue was homog-
enised in 500 mL 0.1 M Tris-HCl pH8 buffer for 2650 seconds at
6000 rpm using a Precelly homogeniser. Tumour lysates were
then centrifuged for 10 min at 14500 rpm at 4uC, supernatants
decanted and the protein content was measured using the DC-
BIORAD protein assay.
For CDA enzyme activity assay, GEM stock solutions were
prepared in water. For each reaction, 20 mL of tumour enzyme
extract was mixed with 170 mL 0.1 M Tris-HCl, 50 mM b-
mercaptoethanol and 10 mL of the appropriate gemcitabine stock
solution to make final GEM substrate concentrations of 50 mM to
5000 mM. Samples were incubated at 37uC for 30 minutes, the
reaction was stopped by adding 600 mL of acetonitrile and 50 mL
of internal standard dFdU-13C, 15N2 was added to each sample.
The same protocol was used to prepare a dFdU standard curve
ranging from 2.5 ng/mL to 5000 ng/mL as well as High
(3500 ng/mL), medium (200 ng/mL) and low (37.5 ng/mL)
quality control dFdU standards.
All samples were mixed and centrifuged at 5000 rpm for 10
minutes at 4uC. 200 mL of supernatant were transferred in a
96 well plate and evaporated to dryness. Samples were then
reconstituted in 200 mL water, vortexed for 5 minutes and the
dFdU was quantified by LC-MS/MS and normalised to the total
protein concentrations.
The in vitro competition assay was performed on an enzyme
extract from an untreated allograft tumour using the protocol
described above. The enzyme extract was mixed with a fixed
concentration of 1800 mM GEM, corresponding to the Km of
CDA in this enzyme extract, and ranging doses of DFCR (0 to
1200 mM) as competitor. The dFdU converted from GEM was
quantified by LC-MS/MS.
Statistical Analysis
Statistical analyses were carried out using GraphPad Prism
version 5.0. Significance of the differences in CAP anti-tumour
efficacy, CDA Vmax and Km for CAP versus vehicle was
determined using an unpaired t-test. In tolerance and GEMCAP
combination studies, distinction in tumour growths were analysed
using a one way ANOVA followed by a Newman-Keuls multiple
comparisons post-test.
Results
Pharmacokinetics and Pharmacodynamics of CAP and its
Metabolites in Mouse Tissues
To investigate the pharmacokinetics of CAP and its metabolites,
we analysed by mass spectrometry the homogenates of plasma,
tumour and liver from mice bearing K8484 allograft tumour
collected at different time points after a single dose of CAP given
orally at 755 mg/kg (2.1 mmol/kg/day). This dose is the human
equivalent dose, determined according to the method of Reagan-
Shaw et al [26]. CAP, DFCR and DFUR were found in the 3
tissues at each time point (Figure 1). Plasma Cmax for DFCR was
393627 mM (20 mins) and for DFUR 125690 mM (40 mins)
(Figure 1A). In tumour tissue, DFCR and DFUR Cmax were
25667 mM and 10167 mM respectively 45 min after CAP
administration and fell to 64.4645.3 mM and 46.4628.1 mM
after 4 h (Figure 1B). In liver, Cmax for all the metabolites were
reached 10 min after dosing and then decreased progressively
(Figure 1C). The concentrations of liver DFCR were higher than
in tumour from the same mice and the liver DFUR concentrations
were lower, consistent with the previously reported distributions of
CES and CDA in tissues [5]. Intra-tumoural concentrations of 5-
FU increased progressively from 12.763.7 mM after 10 min to
49.5 mM after 1 h and fell to 10.763.4 mM after 4 h (Figure 1B).
As our in vitro experiments on K8484 cells showed an IC50 for 5-
FU of 2.5660.55 mM (data not shown), these in vivo results suggest
that an oral CAP dosing delivers a therapeutically effective dose to
the allograft tumours. 5-FU levels were more than 30 fold lower in
plasma (1.960.5 mM at 40 min and 0.360.2 mM after 4 h) than
in tumour and were below the limit of quantification in the liver
from 2 h (Figure 1C). A pharmacodynamic study was also
performed to determine the effect of a single 755 mg/kg CAP
dose on proliferation in K8484 allograft tumours. Tumours were
collected 40 min, 2 h and 4 h after dosing and immunohisto-
chemistry for phospho-histone H3 (PH3) was quantified. PH3
staining was significantly decreased 4 h after dosing (P,0.01;
Figure 1D) compared to control, revealing a decrease in mitotic
cell number following CAP treatment.
It has been shown previously that in situ KPC PDAC tumours
are less sensitive to GEM than KPC allografts despite their
identical Kras and p53 genotypes, and this difference in sensitivity
was attributed to limited drug delivery to the KPC tumours [18].
Therefore, we analysed the amount of CAP and metabolites in
tissues from KPC tumour bearing mice after seven days of CAP
treatment (755 mg/kg). In plasma and liver CAP, DFCR, DFUR
and 5-FU concentrations were comparable between KPC mice
and the allograft hosts 2 h after the last dose (Figure 1E). In KPC
Capecitabine in a Mouse Model of Pancreatic Cancer
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PDAC tumours, 5-FU concentrations were 26.9614.3 mM
(Figure 1E) compared to 23.068.1 mM in KPC allograft tumours,
2 h after a single CAP dose (Figure 1B). Because of the difference
in study protocol (7 doses in KPC mice versus single dose in the
K8484 allografts), we also compared the data with those from an
independent PK study performed after 5 daily doses of CAP
administered in mice bearing K8484 allografts. In this study 5-FU
concentrations in tumour 2 h after the fifth consecutive dose of
CAP was 22.767.7 mM (Figure 1F), equivalent to the 5-FU
concentration after a single dose in allograft tumour (Figure 1B) or
after 7 consecutive doses in KPC tumours (Figure 1E). These data
suggest that multiple doses of CAP did not lead to 5-FU
Figure 1. Pharmacokinetic and pharmacodynamics profiles of CAP in mouse tissues. Metabolite concentrations in plasma (A), K8484
allograft tumour homogenates (B) and liver homogenates (C) after a single dose of CAP at 755 mg/kg. Mean 6 SD (n = 3 except for 45 min and 1 h
where n = 2). (D) Immunohistochemistry for phospho-histone H3 (PH3) quantified in KPC allograft tumours at different time points after a single
755 mg/kg CAP dose. Mean 6 SEM of at least three tumours (**p,0.01). (E) Metabolite concentrations in KPC mouse tissues 2 h after the last of 7
consecutive doses of CAP at 755 mg/kg, Mean and SEM of 6 mice. (F) 5-FU concentrations 2 h after a single dose (solid line) or five consecutive doses
(dashed line) of CAP (755 mg/kg) given to mice bearing K8484 allograft tumours.
doi:10.1371/journal.pone.0067330.g001
Capecitabine in a Mouse Model of Pancreatic Cancer
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accumulation in tumour. These results show that oral CAP
delivered a similar amount of 5-FU to the in situ PDAC tumours
and to the allograft tumours.
CAP Anti-tumour Efficacy in Pancreatic Tumours
We first studied the effect of CAP on the growth of K8484
allograft tumours. Mice were dosed with vehicle or CAP at
755 mg/kg for 5 days per week. After 3 weeks, vehicle-treated
mice exhibited an average tumour volume of 18406201 mm3
compared to 629686 mm3 in CAP-treated mice (Figure 2A), with
a significant increase in tumour doubling time from 3.560.5 days
in vehicle to 7.563.0 days in CAP-treated mice (P = 0.0002;
Figure 2B).
We then proceeded to a short term efficacy study in the in situ
KPC PDAC model. KPC mice were treated with CAP at 755 mg/
kg for 7 consecutive days and tumour volumes were monitored
twice a week by 3D ultrasonography. Tumour growth was reduced
in CAP-treated KPC mice compared to the vehicle-treated mice
(Figure 3A). The volume of CAP- treated tumours was
121610.2% compared to 199621.8% in control (p,0.01;
Figure 3B). Tumour tissue was collected 2 hours after the last
dose of CAP. PH3 staining revealed less cells in mitosis in CAP-
treated tumours compared to control (p,0.05; Figure 3C),
suggesting growth arrest.
The Effect of CAP Administration on KPC Mice Survival
Compared to GEM
Our pharmacokinetic data showed efficient 5-FU delivery and
the short term CAP efficacy study data led us to compare CAP to
GEM in a longer term study, using survival as the end-point. KPC
mice were treated either with CAP at 755 mg/kg for 5 days per
week or with 100 mg/kg GEM every 3 days. Results identified
that survival was similar in the 2 groups; median survival 8 and
10.5 days for CAP and GEM respectively, P= 0.61 (Figure 4A).
The longest survival was 67 days in the CAP group compared to
26 days in the GEM group. Furthermore, there was no difference
in tumour growth between CAP- and GEM- treated groups
(Figure 4B), suggesting similar efficacy of GEM and CAP in PDA.
Effect of the GEMCAP Combination
Next, the combination of GEMCAP was investigated. In order
to choose the appropriate doses, we first investigated the
tolerability of the combination in mice bearing K8484 allografts.
Mice were treated with GEM at 100 mg/kg every 3 days alone or
in combination with CAP given 5 days per week at 755 mg/kg,
539 mg/kg or 378 mg/kg. All three combinations using full dose
GEM induced marked gastrointestinal toxicity indicated by mouse
body weight loss and the histology of the mouse small intestine:
shortened villi with disrupted architecture and crypt loss (Supple-
mental Figure S1 D, F). Neither CAP 755 mg/kg or GEM
100 mg/kg alone showed any gastrointestinal toxicity (Figure S1,
A – C) Therefore, we repeated the experiment with the same CAP
doses combined with reduced GEM dose (75 mg/kg). The
combination group treated with 755 mg/kg CAP showed early
toxicity, confirmed by the small intestine histology (Figure S1, G).
The combination with 539 mg/kg CAP (71% of full dose)
exhibited no signs of toxicity over two cycles of treatment
(11 days). Based on these results, we therefore used the safer
doses of 539 mg/kg CAP and 75 mg/kg GEM to study the
efficacy of the GEMCAP combination in mice with K8484
allografts. After 3 weeks, GEM significantly reduced tumour
growth (p,0.001) compared to vehicle, as did CAP alone
(p,0.05) (Figure 5). The difference observed between GEM and
CAP alone was not significant (P.0.05). The GEMCAP
combination significantly inhibited the tumour growth with
tumour doubling time of 8.6610.8 days (compared to
2.760.9 days in control) but this was not superior to GEM alone
(tumour doubling time of 7.262.8 days) and not significantly
different from CAP alone. During the 3rd week of treatment, mice
treated with the GEMCAP combination started to show toxicity
(weight loss), compared to single agent treated mice but intestinal
histology at the endpoint appeared normal (Figure S1, H and I).
These data, showing a lack of synergy of the combination, are
consistent with those from in vitro cytotoxicity assays we performed
on K8484 cells and human pancreatic cell lines (MiaPaCa-2 and
Panc-1) dosed with a range of 5-FU and GEM combinations,
where additive but not synergistic effects were observed (Figure
S2). Taken together, our results showed additive cytotoxic effect
in vitro but also additive toxicity in vivo. Therefore, GEMCAP does
not lead to improved therapeutic index in mice when compared to
GEM alone.
We then investigated tumour CDA activity. Using GEM as a
substrate, we determined the conversion rate of GEM into dFdU
and the kinetic constants of CDA, Vmax and Km, in vehicle- and
CAP-treated allograft tumours (Figure 6). Results showed reduced
Figure 2. Anti-tumour effect of capecitabine in KPC allograft tumours. (A) Capecitabine efficacy in mice bearing K8484 allograft tumours.
Animals received 755 mg/kg daily for 5 consecutive days per week for 3 weeks. Tumour volumes are represented as the mean 6 SEM of 12 vehicle-
and 13 CAP-treated mice (**p,0.01). (B) The tumour doubling time for each tumour (***p,0.001).
doi:10.1371/journal.pone.0067330.g002
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Vmax and Km in CAP-treated tumours (15.162.6 nmol/h/mg
protein and 13206147 mM respectively) compared to untreated
tumours (56.367.2 nmol/h/mg protein and 1880682 mM re-
spectively; Figure 6C and 6D) suggesting that the gemcitabine
metabolising capacity of CDA was decreased in transplanted
PDAC tumours during CAP treatment. As the tumours were
collected between 2 h and 4 h after the last dose of CAP, we
wondered if the reduced activity was due to competition between
the added GEM substrate and the DFCR already in the tumours.
We therefore performed an in vitro competition assay using the
enzyme extract from an untreated allograft tumour, a fixed GEM
concentration of 1800 mM corresponding to the Km of CDA in
the enzyme extract and DFCR concentrations ranging from 0 to
1200 mM. Results, presented in Figure 6E, showed minimal
changes in the conversion rate of GEM into dFdU even in the
presence of the highest concentration of DFCR. The LC-MS/MS
analyses of CAP-treated tumours revealed that the highest DFCR
concentrations was 511 mM, within the range tested in this
competition assay, supporting that the observed decrease in CDA
activity in CAP-treated tumours was not related to a substrate
competition. This suggests that CAP treatment may downregulate
CDA activity.
Because of the in vivo toxicity and the lack of enhanced effect of
GEMCAP compared to GEM alone in the allografts, we did not
test GEMCAP in KPC PDAC mice, whose health is less robust.
Discussion
The studies presented here provide, for the first time, pre-
clinical data on the pharmacokinetics and the efficacy of
capecitabine in a genetically engineered mouse model of PDAC.
We used the KrasG12D; Trp53R172H; Pdx1-Cre mouse model [12],
because it recapitulates the clinical syndrome and histopathology
of the human disease. Our pharmacokinetic data showed that,
after oral administration, CAP undergoes extensive metabolism in
plasma, liver and tumour. Concentrations of CAP metabolites in
each of these compartments are consistent with those found in a
human colon cancer xenograft [27]. They are also consistent with
the previously reported distribution of the enzymes involved in the
CAP metabolism in human and mouse [5,27]. 5-FU was found at
higher levels in tumour than in plasma from 30 min post
administration and was undetectable in the liver confirming the
tumour selective delivery of 5-FU after CAP administration also
described by Ishikawa et al. [6]. The low 5-FU in plasma and liver
may account for the low toxicity of CAP at the dose of 755 mg/kg:
none of the mice showed signs of toxicity due to CAP treatment
alone. We did not test higher doses because 755 mg/kg
(2.1 mmol/kg) has been reported as the MTD [28].
We found equivalent concentrations of 5-FU in both KPC
allograft and in situ PDAC tumours after CAP dosing. This finding
was unexpected as impaired drug delivery has been reported in
KPC tumours compared to allograft tumours after GEM dosing
Figure 3. Anti-tumour effect of capecitabine in in situ PDAC tumours. (A) Short term capecitabine efficacy study in KPC mice with in situ
PDAC, dosed with 755 mg/kg for 7 consecutive days. Tumour volumes for vehicle and CAP were measured by ultrasound and normalized to the
tumour volume at the day of the enrolment in study (mean 6 SEM, n = 6 per group). (B) Tumour volume at the endpoint as a percentage of the
volume at the start, in KPC mice treated with vehicle or CAP (mean 6 SEM, n = 6 in each group; **p,0.01). (C) Immunohistochemistry for phospho-
histone H3 was quantified in PDAC tumours 2 h after the 7th and last dose of CAP 755 mg/kg. Results are expressed as the mean 6 SEM (n= 6 per
group; *p = 0.027).
doi:10.1371/journal.pone.0067330.g003
Capecitabine in a Mouse Model of Pancreatic Cancer
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e67330
[18]. However, oral dosing of CAP extends systemic exposure time
and may result in more sustained delivery to the tissues, leading to
saturation in tissue compartments, than the bolus I.P. injection of
GEM, which is cleared quickly. Impaired GEM delivery was
attributed to poor vascularisation and the thickness of the stroma
in PDAC tumours [18]. These factors should also affect 5-FU
delivery. We also analysed the 5-FU content in different parts of
the same in situ PDA tumour by mass spectroscopy and found
homogeneous 5-FU concentrations, further supporting the
hypothesis that prolonged administration leads to tissue saturation.
According to our experiments on GEM pharmacokinetics (not
shown), the concentration of the active GEM metabolite,
dFdCTP, was 2.3561.21 mM in KPC allografts, 2 h after GEM
dosing which is about 10 times less than the 5-FU concentration
we found in these tumours at the same time after CAP dosing.
Despite this difference, CAP induced a similar anti-tumour
efficacy to GEM. This observation can be correlated to our
in vitro data showing that in K8484 cells, the GEM IC50 is lower
(1.461.8 nM) than the 5-FU IC50 (2.5660.55 mM). It suggests
that, although CAP and GEM were delivered to the tumour at
therapeutically effective doses, higher doses of CAP are necessary
to achieve the same anti-tumour effect than GEM.
CAP as a single agent was well tolerated in mice and induced
similar effect to GEM on pancreatic tumour growth. This latter
observation is supported by the results of a phase II clinical study
in which 24% of patients with advanced PDAC and treated with
CAP monotherapy had a clinical benefit response [29]. This
clinical response rate was similar to the 23.8% reported for single
agent GEM [30].
In view of clinical practice in the UK, we were keen to study the
effect of the GEMCAP combination in our preclinical models.
The combination of a nucleoside analogue with agents increasing
nucleoside transporter (NT) expression at the cell surface has the
potential for increased cytotoxicity. It has been shown that 5-FU
depletes the endogenous intracellular nucleotide pools leading to
increased NT abundance at the cell surface [31–33], and NT
activity is a prerequisite for growth inhibition by GEM in vitro [34].
However, the in vitro data we have presented did not show any
synergy between 5-FU and GEM. Rauchwerger et al. showed that
5-FU added prior to GEM, in Panc-1 cells, increased cell surface
NT content and cytotoxicity to GEM but 5-FU doses used in that
study (30 mM and 100 mM) were more than 100 fold higher than
the 5-FU IC50 [33].
In vivo, significant toxicity was seen when GEM was combined
with CAP and, as a result, reduced doses were required in
combination, which showed no benefit in anti-tumour activity
when compared to GEM alone. The meta-analysis performed by
Heinemann et al. showed a significant survival benefit from the
GEMCAP combination [2], based on phase III studies which
individually showed a modest benefit [35] or only a trend in
improving the overall survival and with an increase in toxicity for
patients under GEMCAP treatment [36].
When GEM and CAP are combined, it is relevant to consider
the role of cytidine deaminase (CDA), which is involved in the
metabolism of both drugs. CDA plays a key role in the activation
of CAP, through the deamination of DFCR to DFUR, and
inactivates GEM through the deamination to dFdU [4,5,16,17].
Therefore GEM and CAP metabolism may vary, according to the
level of CDA activity in the relevant tissue. Transfection of human
CDA into gastric cancer cell lines reduced their sensitivity to GEM
both in vitro and in vivo [37] and forced expression of CDA
increased the sensitivity of bladder cancer cells to DFCR but made
them resistant to GEM in vitro and in vivo [38]. Our data suggests
that the gemcitabine metabolising capacity of CDA was decreased
in transplanted PDAC tumours during CAP treatment. Regula-
tion of CDA activity by drug treatment has been described
previously. Frese et al. demonstrated that nab-paclitaxel reduced
the level of CDA expression in PDA tumours resulting in an
Figure 4. Comparison of CAP and GEM on KPC mice survival.
(A): Kaplan-Meier curves for capecitabine (hatched) and gemcitabine
(solid) survival. P = 0.61 Log-Rank test, Hazard Ratio = 0.78, 95%CI 0.29
to 2.06 (n = 10 per group). (B): Individual growth curves for CAP- (black)
and GEM-treated tumours (red). Volumes were normalized to the
volume at the day of the enrolment in the survival study.
doi:10.1371/journal.pone.0067330.g004
Figure 5. Anti-tumour effect of the GEMCAP combination in
KPC allograft. GEMCAP combination efficacy in mice bearing KPC
allograft tumours. Animals received vehicle or GEM every 3 days at
75 mg/kg or CAP at 539 mg/kg, 5 days per week or a combination of
these two doses. Tumour volumes are represented as the mean 6 SEM
(n= 5 per group; *p,0.05, ***p,0.001 when compared to vehicle; ns:
not significant).
doi:10.1371/journal.pone.0067330.g005
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increase of intra-tumoural GEM metabolites. In vitro experiments
showed that CDA was inactivated through an induction of reactive
oxygen species (ROS) [39]. 5-FU was shown to induce apoptosis
through increase of intracellular ROS production in Jurkat cells,
lung and colorectal cancer cells [40–42]. These data suggest that
after treatment by CAP, 5-FU may induce ROS in KPC allografts,
resulting in decreased activity of CDA.
A CAP-induced decrease in CDA activity could lead to
improved anti-tumour efficacy with the GEMCAP combination,
but also may explain the increased toxicity associated with the
GEMCAP combination in our studies as, in mice, high CDA
activity is seen in the intestine [43]. Supporting this hypothesis,
patients with CDA deficiency experience severe toxicities after
GEM-based chemotherapies [14].
In summary, our pre-clinical data support the use of CAP in the
treatment of PDAC, although we were unable to demonstrate, in
these models, a benefit for the combination with GEM, because
increased toxicity forced dose reduction of both agents. In view of
the activity seen as a single agent, CAP could be considered as an
alternative to GEM in future combination treatment strategies,
where a fluoropyrimidine may be a more rational partner for
novel agents than GEM.
Supporting Information
Figure S1 Histology of small intestine from GEMCAP-
treated mice. H&E stained sections showing the small intestine
architecture after administration of vehicle (A), CAP 755 mg/kg
(B), GEM 100 mg/kg (C), GEM 100 mg/kg and CAP 755 mg/kg
(D), GEM 100 mg/kg and CAP 539 mg/kg (E), GEM 100 mg/kg
and CAP 378 mg/kg (F), GEM 75 mg/kg and CAP 755 mg/kg
(G), GEM 75 mg/kg and CAP 539 mg/kg (H) and GEM 75 mg/
kg and CAP 378 mg/kg (I).
(TIF)
Figure S2 Evaluation of GEMCAP combination in
mouse and human pancreatic cancer cell lines in vitro.
K8484 (A), Panc-1 (B) and MIAPaCa-2 (C) cells were exposed to
combinations of concentrations of GEM (0–300 nM) and 5-FU
(0–30,000 nM) for 72 h then SRB staining was used to determine
the % of growth compared to solvent control (1). Predicted growth
inhibitions were calculated using the Bliss Additivity model with
the single agent data (2) and then subtracted from the
experimental data to give a difference value for each combination
(3). The numbers in each square are the mean and standard
deviation of 3 replicates and each square is colour-coded
according to the heatmap of the difference values (scale shown
on the right). Negative difference values, shown in blue would
denote synergy and positive difference values, shown in red, would
denote antagonism.
(TIF)
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